Skip to main content
915 TLDR
Health
1 read

FDA Fast-Tracks Psychedelic Drugs for Mental Health Treatments in the U.S.

KVIACNN Newsource
Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

Read Original

AI Summary

The FDA has initiated a significant step towards the approval of psychedelic drugs as mental health treatments by issuing national priority vouchers to three companies. These include psilocybin for treatment-resistant depression and methylone for PTSD. This move, part of a pilot program aimed at expediting the review process, is crucial as it could provide new options for patients struggling with severe mental health issues. Additionally, an early phase clinical study of ibogaine for alcohol use disorder has been approved, marking a milestone in psychedelic research. Health officials emphasize the importance of rigorous clinical evidence as these treatments are explored.

Key Details: • FDA issued priority vouchers for psilocybin and methylone on Friday. • Ibogaine clinical study for alcohol use disorder is now allowed to proceed. • Psychedelic drugs are currently classified as Schedule I substances. • Executive order signed by President Trump aims to accelerate research and access to these treatments.

mental-health treatment research fda psychedelics

People & Organizations

Donald TrumpFDAColumbia UniversityMarty MakaryRobert F. Kennedy, Jr.Melissa LavasaniDavid HellersteinPsychedelic Medicine CoalitionNew York State Psychiatric Institute

Related Articles